Kirkland & Ellis is advising international investment firm BC Partners on the sale of Pharmathen, a leading European pharmaceutical company, to global private markets firm Partners Group (acting on behalf of its clients). The transaction values the business at c. €1.6 billion.

Pharmathen is the leading European drug delivery technology company. With a highly differentiated business model and strong management team, the company is a specialist in the development of “sustained release” technologies, with best-in-class R&D capabilities, serving a blue-chip customer base in nearly 100 countries worldwide. The transaction is subject to receipt of customary regulatory approvals and is expected to close in 2021.